KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Liabilities and Shareholders Equity (2016 - 2026)

Neogenomics filings provide 17 years of Liabilities and Shareholders Equity readings, the most recent being $1.3 billion for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 15.92% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.5 billion, a 16.08% decrease, with the full-year FY2025 number at $1.4 billion, down 16.98% from a year prior.
  • Liabilities and Shareholders Equity hit $1.3 billion in Q1 2026 for Neogenomics, down from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q1 2022 to a low of $1.3 billion in Q1 2026.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.6 billion (2024), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: increased 22.43% in 2022 and later fell 16.98% in 2025.
  • Neogenomics' Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025, then decreased by 0.98% to $1.3 billion in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025) per Business Quant data.